

SUBJECT: CONSENT AGENDA – REVISED AS AT 22 JUNE 2021

Agenda item: 01f

Category: For Decision

Section A: Introduction

Seven recommendations are being presented to the Board under the Consent Agenda for consideration. Detailed information on the items can be found in the relevant Committee paper in a dedicated folder on BoardEffect at:

https://gavi.boardeffect.co.uk/workrooms/6459/resources/127300

Section B: Actions requested of the Board

The Gavi Alliance Board is requested to consider the following recommendations from the Gavi Alliance Governance Committee, Audit and Finance Committee and Programme and Policy Committee.

<u>Decision One – Board and Committee Member Appointments</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) Appoint Awa Marie Coll Seck as an Unaffiliated Board member in the seat currently held by Stephen Zinser effective 1 July 2021 and until 30 June 2024
- b) Appoint Naguib Kheraj as an Unaffiliated Board member in the seat currently held by William Roedy effective 1 August 2021 and until 31 July 2024
- c) <u>Appoint</u> Bounfeng Phoummalaysith of Lao PDR as Alternate Board Member representing the implementing country constituency in the seat formerly held by Bounkong Syhavong of Lao PDR, effective immediately and until 31 December 2023
- d) **Appoint** the following to the Governance Committee effective 1 August 2021:
 - An Vermeersch (Alternate Board Member) until 31 December 2021
- e) **Appoint** the following to the Audit and Finance Committee effective 1 August 2021:
 - Naguib Kheraj (Board Member) until 31 December 2021



- f) Appoint the following to the Investment Committee effective 1 August 2021:
 - Naguib Kheraj (Board Member) until 31 December 2021
- g) **Appoint** the following to the Programme and Policy Committee:
 - **Ephrem Lemango** (Committee Delegate) effective immediately and until 31 Dec 2021
 - Awa Marie Coll Seck (Board Member) effective 1 July 2021 and until 31 Dec 2021

<u>Decision Two - Committee Chair Appointments</u>

The Gavi Alliance Governance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) <u>Appoint</u> Afsaneh Beschloss as Chair of the Investment Committee effective
 1 July 2021 and until 31 December 2021; and
- b) **Appoint James Hargreaves** as Chair of the Evaluation Advisory Committee effective 1 July 2021 and until 31 December 2021.

<u>Decision Three – UNICEF Procurement Fees</u>

The Gavi Alliance Audit and Finance Committee <u>recommends</u> to the Gavi Alliance Board that it:

- a) **Approve**, within the overall Partners Engagement Framework,
 - i. the proposed UNICEF procurement fee of US\$ 28.7 million for 2022;
 - ii. A budget of US\$ 24.4 million for UNICEF Supply Division fees for the procurement of vaccines, related devices and yellow fever surveillance and diagnostics equipment in 2022; and
 - iii. A budget of US\$ 4.3 million for UNICEF Supply Division fees for the procurement of cold chain equipment for 2022.
- Note that the procurement fee excludes any procurement activity related to COVAX.



Decision Four - Yellow Fever

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve an extension through the end of 2022 of the currently forecasted amount which remains within the initially approved envelope of US\$ 8.2 million authorised for the 2019-2021 period for costs related to the procurement and distribution of laboratory reagents, supplies, and equipment for yellow fever diagnostic capacity strengthening through a diagnostic procurement mechanism based on Gavi's existing application, review, and approval processes as set forth in Annex A to Doc 01f.

Decision Five – Gavi 5.0 Measurement Framework

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it <u>approve</u> the proposed targets for selected Gavi 5.0 mission and strategy performance indicators in Annex B to Doc 01f, noting that:

- a) The targets will be measured against a 2019 baseline;
- b) The targets are aligned with Immunization Agenda (IA) 2030;
- c) The targets are established under the assumption that COVID-19-related disruptions to immunisation programmes will be limited in 2021 and beyond; however if they are greater or extend longer than assumed the Secretariat may request the Board to adjust the targets; and
- d) Targets for remaining mission and strategy performance indicators in Annex C to Doc 01f will be brought for approval later this year.

Decision Six – Gavi 5.0: Market Shaping Strategy

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve the Market Shaping Strategy 5.0 as set out in Annex D to Doc 01f.



<u>Decision Seven - Vaccine Innovation Prioritisation Strategy</u>

The Gavi Alliance Programme and Policy Committee <u>recommends</u> to the Gavi Alliance Board that it:

Approve an initial investment of up to US\$ 5 million for the Vaccine Innovation Prioritisation Strategy (VIPS) for costs related to short-term (2021-2023) activities to provide guidance for and incentivise development of the three VIPS innovation priorities, namely clarifying the potential demand and willingness-to-pay, defining investment cases and understanding the need for and design of push and pull funding mechanisms, and generating evidence of programmatic impact, pending confirmation of availability of funding by the Gavi Alliance Audit and Finance Committee (AFC) at its meeting on 7 June 2021.